Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives |
| |
| Authors: | Giandomenico Roviello Karol Polom Roberto Petrioli Luigi Marano Daniele Marrelli Giovanni Paganini Vinno Savelli Daniele Generali Lorenzo De Franco Andrea Ravelli Franco Roviello |
| |
| Affiliation: | 1.Section of pharmacology and University Center DIFF—Drug Innovation Forward Future, Department of Molecular and Translational Medicine,University of Brescia,Brescia,Italy;2.Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery,University of Siena,Siena,Italy;3.Medical Oncology Unit,University of Siena,Siena,Italy;4.General, Minimally Invasive and Robotic Surgery, Department of Surgery,“San Matteo degli Infermi” Hospital,Spoleto,Italy;5.Department of Medical, Surgical and Neurosciences, Section of Advanced Surgical Oncology,University of Siena,Siena,Italy;6.Unit of General Medicine,Azienda Ospedaliera “C. Poma ” Presidio ospedaliero di Pieve di Coriano,Mantova,Italy;7.Department of Surgery and Bioengineering, Section of Surgery,University of Siena,Siena,Italy;8.Department of Medical, Surgery and Health Sciences,University of Trieste,Trieste,Italy;9.Department of Clinical and Experimental Medicine,University of Parma,Parma,Italy |
| |
| Abstract: | Gastric cancer (GC) is the second leading cause of cancer-related death, and despite having improved treatment modalities over the last decade, for most patients, only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and the related signaling pathways offers, from the clinical point of view, promising advances for selected groups of patients. In the past, targeted therapies have significantly impacted the treatment strategy of several common solid tumors such as breast, colorectal, and lung cancers. Unfortunately, translational and clinical research shows fewer encouraging targeted treatments with regards to the GC. To date, only two monoclonal antibodies (mAb), named trastuzumab and ramucirumab, are approved for the treatment of advanced GC, suggesting that in GC, maybe more than in other cancers, effective targeted therapy requires patient selection based on precise predictive molecular biomarkers. The aim of this review is to summarize the available data on the clinical advantages offered by the use of mAbs in the treatment of advanced/metastatic GC. Future perspective is also discussed. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
